198 related articles for article (PubMed ID: 28673798)
1. Rapid Response to Nivolumab in a Patient With Sarcomatoid Transformation of Chromophobe Renal Cell Carcinoma.
Rouvinov K; Osyntsov L; Shaco-Levy R; Baram N; Ariad S; Mermershtain W
Clin Genitourin Cancer; 2017 Dec; 15(6):e1127-e1130. PubMed ID: 28673798
[No Abstract] [Full Text] [Related]
2. Anti-programmed Cell Death Protein 1 (PD-1) Antibody Nivolumab Leads to a Dramatic and Rapid Response in Papillary Renal Cell Carcinoma with Sarcomatoid and Rhabdoid Features.
Geynisman DM
Eur Urol; 2015 Nov; 68(5):912-4. PubMed ID: 26194044
[No Abstract] [Full Text] [Related]
3. Significant response to nivolumab for metastatic chromophobe renal cell carcinoma with sarcomatoid differentiation: a case report.
Noguchi G; Tsutsumi S; Yasui M; Ohtake S; Umemoto S; Nakaigawa N; Yao M; Kishida T
BMC Urol; 2018 Apr; 18(1):26. PubMed ID: 29669553
[TBL] [Abstract][Full Text] [Related]
4. Chromophobe renal cell carcinoma with sarcomatoid transformation.
Abrahams NA; Ayala AG; Czerniak B
Ann Diagn Pathol; 2003 Oct; 7(5):296-9. PubMed ID: 14571432
[TBL] [Abstract][Full Text] [Related]
5. Safety and Efficacy of Nivolumab in Patients With Metastatic Renal Cell Carcinoma Treated Beyond Progression: A Subgroup Analysis of a Randomized Clinical Trial.
George S; Motzer RJ; Hammers HJ; Redman BG; Kuzel TM; Tykodi SS; Plimack ER; Jiang J; Waxman IM; Rini BI
JAMA Oncol; 2016 Sep; 2(9):1179-86. PubMed ID: 27243803
[TBL] [Abstract][Full Text] [Related]
6. Nivolumab treatment for advanced renal cell carcinoma: Considerations for clinical practice.
Joseph RW; Chatta G; Vaishampayan U
Urol Oncol; 2017 Apr; 35(4):142-148. PubMed ID: 28259541
[TBL] [Abstract][Full Text] [Related]
7. Nivolumab in the treatment of advanced renal cell carcinoma.
Arasaratnam M; Gurney H
Future Oncol; 2018 Jul; 14(17):1679-1689. PubMed ID: 29460635
[TBL] [Abstract][Full Text] [Related]
8. Nivolumab: The New Second Line Treatment for Advanced Renal-cell Carcinoma Commentary on: Nivolumab Versus Everolimus in Advanced Renal-cell Carcinoma.
Chedgy EC; Black PC
Urology; 2016 Mar; 89():8-9. PubMed ID: 26723186
[No Abstract] [Full Text] [Related]
9. PD-1 and PD-L1 Expression in Renal Cell Carcinoma with Sarcomatoid Differentiation.
Joseph RW; Millis SZ; Carballido EM; Bryant D; Gatalica Z; Reddy S; Bryce AH; Vogelzang NJ; Stanton ML; Castle EP; Ho TH
Cancer Immunol Res; 2015 Dec; 3(12):1303-7. PubMed ID: 26307625
[TBL] [Abstract][Full Text] [Related]
10. The 'nivolution' in renal cell carcinoma: behind the scenes of clinical trials.
Buti S; Bersanelli M
Future Oncol; 2016 Sep; 12(18):2061-3. PubMed ID: 27168416
[No Abstract] [Full Text] [Related]
11. Sarcomatoid differentiation of renal cell carcinoma: a clinical case with literature review.
Kountourakis P; Kandylis K; Daskalopoulou D; Rigatos G
J BUON; 2008; 13(2):281-3. PubMed ID: 18555479
[TBL] [Abstract][Full Text] [Related]
12. Cabozantinib and nivolumab for renal cell carcinoma.
Worley L
Lancet Oncol; 2015 Nov; 16(15):e531. PubMed ID: 26481805
[No Abstract] [Full Text] [Related]
13. Words of Wisdom. Re: Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.
Bedke J; Stenzl A
Eur Urol; 2016 Mar; 69(3):538-9. PubMed ID: 26867725
[No Abstract] [Full Text] [Related]
14. Chromophobe renal cell carcinoma with sarcomatoid dedifferentiation treated with pazopanib: a case report.
Matrana MR; Ng C; Rao P; Lim ZD; Tannir NM
Clin Genitourin Cancer; 2011 Dec; 9(2):137-9. PubMed ID: 21831725
[No Abstract] [Full Text] [Related]
15. Negative prognostic factors and resulting clinical outcome in patients with metastatic renal cell carcinoma included in the Italian nivolumab-expanded access program.
Bracarda S; Galli L; Maruzzo M; Lo Re G; Buti S; Favaretto A; Di Costanzo F; Sacco C; Merlano M; Mucciarini C; Zafarana E; Romito S; Maestri A; Giorgio CG; Ionta MT; Turci D; De Giorgi U; Procopio G; Cortesi E; Giannarelli D; Porta C
Future Oncol; 2018 Jun; 14(14):1347-1354. PubMed ID: 29774766
[TBL] [Abstract][Full Text] [Related]
16. [Drug treatment of metastatic renal cell carcinoma].
Rafiyan MR; Jäger E
Dtsch Med Wochenschr; 2013 Aug; 138(31-32):1567-70. PubMed ID: 23836159
[No Abstract] [Full Text] [Related]
17. Words of Wisdom. Re: Nivolumab Versus Everolimus in Advanced Renal-Cell Carcinoma.
Mulders PF
Eur Urol; 2016 Apr; 69(4):753-4. PubMed ID: 26972496
[No Abstract] [Full Text] [Related]
18. Progress in the management of advanced renal cell carcinoma (RCC).
Tong TQ; Rohde D; Peter S
Aktuelle Urol; 2010 Jan; 41 Suppl 1():S57-60. PubMed ID: 20094957
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics, pharmacodynamics and clinical efficacy of nivolumab in the treatment of metastatic renal cell carcinoma.
Farolfi A; Schepisi G; Conteduca V; Burgio SL; Lolli C; De Giorgi U
Expert Opin Drug Metab Toxicol; 2016 Sep; 12(9):1089-96. PubMed ID: 27450183
[TBL] [Abstract][Full Text] [Related]
20. [Metastatic renal cell carcinoma, back to the future].
Martins F; Berthold D
Rev Med Suisse; 2016 May; 12(519):994-8. PubMed ID: 27424427
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
